Ligand Pharma (LGND) Tops Q2 EPS by 84c

Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.42, $0.84 better than the analyst estimate of $0.58. Revenue for the quarter came in at $26.4 million versus the consensus estimate of $24.74 million.

GUIDANCE:

Ligand Pharma sees FY2023 EPS of $4.85-$5.00, versus the consensus of $4.63. Ligand Pharma sees FY2023 revenue of $124-128 million, versus the consensus of $131 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Norwegian Cruise Line rating cut at Mizuho after 'self-inflicted wounds'
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance